Polymeric Nanoparticle CAR T Immunotherapy Platform

Alaya.bio is focused on developing innovative CAR-T therapies utilizing a specialized targeting polymeric nanoparticle technology. This nanoparticle is designed to enhance the transduction efficiency of quiescent immune cells, such as T-cells and NK-cells, while maintaining their naive and memory phenotypes. The versatility of this technology allows for its application in both ex vivo and in vivo settings, potentially improving the effectiveness of immunotherapies by optimizing the activation and functionality of these critical immune cells.

As a preclinical-stage biotech company, Alaya.bio is positioned to make significant contributions to the field of cancer treatment through its novel approaches to CAR-T therapy. Co-founded by experienced professionals Dr. Cécile Bauche and Renaud Vaillant, the company is leveraging their extensive expertise in gene delivery technologies and biotech innovation. With a focus on advancing its in vivo CAR immunotherapy platform, Alaya.bio aims to address current challenges in CAR-T therapies, including cost and manufacturing efficiency, thereby enhancing patient outcomes in cancer treatment.

United States

At Alaya.bio, we're developing a revolutionary targeting polymeric nanoparticle that enhances the transduction efficiency of quiescent cells such as T-cells, NK-cells, and stem cells. Our platform eliminates the need for activation factors or cytokines, resulting in reduced exhaustion of transduced cells while preserving their naive and memory phenotypes, leading to better clinical outcomes.

Alaya.bio

Company Details